These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 16985555)

  • 1. Chemopreventive trials in urologic cancer.
    Ashughyan VR; Marihart S; Djavan B
    Rev Urol; 2006; 8(1):8-13. PubMed ID: 16985555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemoprevention using dutasteride: the REDUCE trial.
    Gomella LG
    Curr Opin Urol; 2005 Jan; 15(1):29-32. PubMed ID: 15586026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride.
    Musquera M; Fleshner NE; Finelli A; Zlotta AR
    Expert Rev Anticancer Ther; 2008 Jul; 8(7):1073-9. PubMed ID: 18588452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Chemoprevention of prostate cancer].
    Djavan B; Thompson I; Michel MS; Waldert M; Seitz C
    Urologe A; 2004 May; 43(5):557-61. PubMed ID: 15042290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapeutic prevention studies of prostate cancer.
    Djavan B; Zlotta A; Schulman C; Teillac P; Iversen P; Boccon Gibod L; Bartsch G; Marberger M
    J Urol; 2004 Feb; 171(2 Pt 2):S10-3; discussion S13-4. PubMed ID: 14713746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of phase III clinical trials of prostate cancer chemoprevention.
    Thorpe JF; Jain S; Marczylo TH; Gescher AJ; Steward WP; Mellon JK
    Ann R Coll Surg Engl; 2007 Apr; 89(3):207-11. PubMed ID: 17394699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Finasteride as a chemopreventive agent in prostate cancer: impact of the PCPT on urologic practice.
    Goetzl MA; Holzbeierlein JM
    Nat Clin Pract Urol; 2006 Aug; 3(8):422-9. PubMed ID: 16902518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on prostate cancer chemoprevention.
    Lowe JF; Frazee LA
    Pharmacotherapy; 2006 Mar; 26(3):353-9. PubMed ID: 16503715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can we prevent prostate cancer? Rationale and current status of prostate cancer chemoprevention.
    Fujimoto N; Chang C; Nomura M; Matsumoto T
    Urol Int; 2005; 74(4):289-97. PubMed ID: 15897691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial.
    Andriole G; Bostwick D; Brawley O; Gomella L; Marberger M; Tindall D; Breed S; Somerville M; Rittmaster R;
    J Urol; 2004 Oct; 172(4 Pt 1):1314-7. PubMed ID: 15371831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemoprevention of prostate cancer.
    Kucuk O
    Cancer Metastasis Rev; 2002; 21(2):111-24. PubMed ID: 12465750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on chemoprevention for prostate cancer.
    Strope SA; Andriole GL
    Curr Opin Urol; 2010 May; 20(3):194-7. PubMed ID: 20216317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dutasteride: a review of current data on a novel dual inhibitor of 5alpha reductase.
    Marihart S; Harik M; Djavan B
    Rev Urol; 2005; 7(4):203-10. PubMed ID: 16985831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate cancer chemoprevention: current status and future prospects.
    Gupta S
    Toxicol Appl Pharmacol; 2007 Nov; 224(3):369-76. PubMed ID: 17189645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dutasteride: a novel dual inhibitor of 5alpha-reductase for benign prostatic hyperplasia.
    Djavan B; Milani S; Fong YK
    Expert Opin Pharmacother; 2005 Feb; 6(2):311-7. PubMed ID: 15757426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
    Bartsch G; Rittmaster RS; Klocker H
    World J Urol; 2002 Apr; 19(6):413-25. PubMed ID: 12022710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemoprevention of prostate cancer.
    Vemana G; Hamilton RJ; Andriole GL; Freedland SJ
    Annu Rev Med; 2014; 65():111-23. PubMed ID: 24188663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of dutasteride on prostate carcinoma primary cultures: a comparative study with finasteride and MK386.
    Festuccia C; Gravina GL; Muzi P; Pomante R; Angelucci A; Vicentini C; Bologna M
    J Urol; 2008 Jul; 180(1):367-72. PubMed ID: 18499161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction in the risk of prostate cancer: future directions after the Prostate Cancer Prevention Trial.
    Crawford ED; Andriole GL; Marberger M; Rittmaster RS
    Urology; 2010 Mar; 75(3):502-9. PubMed ID: 20035983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A tale of two trials: The impact of 5α-reductase inhibition on prostate cancer (Review).
    Lacy JM; Kyprianou N
    Oncol Lett; 2014 Oct; 8(4):1391-1396. PubMed ID: 25202340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.